Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim A Papp

Showing results (51-60 of 219) with videos related to

Pageof 22
Sort By:
Journal of the American Academy of Dermatology|November 27, 2002
A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisGerald G Krueger, Kim A Papp, Dow B Stough, et al.
Journal of Cutaneous Medicine and Surgery|April 25, 2006
Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approachesRichard G Langley, Vincent Ho, Charles Lynde, et al.
American Journal of Clinical Dermatology|November 13, 2018
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 StudiesApril W Armstrong, Kristian Reich, Peter Foley, et al.
American Journal of Clinical Dermatology|September 8, 2019
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II StudyMark G Lebwohl, Andrew Blauvelt, Alan Menter, et al.
Journal of Cutaneous Medicine and Surgery|February 23, 2018
OBSERVE-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United StatesKim A Papp, Marc Bourcier, Yves Poulin, et al.
Journal of the American Academy of Dermatology|September 21, 2010
Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult populationKim A Papp, Yves Poulin, Robert Bissonnette, et al.
The Journal of Dermatological Treatment|July 15, 2020
Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1Christopher E M Griffiths, Kim A Papp, Michael Song, et al.
Journal of the American Academy of Dermatology|July 21, 2015
Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasisAlan Menter, Diamant Thaçi, Kim A Papp, et al.
Journal of the American Academy of Dermatology|July 6, 2010
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendationsMark Lebwohl, Newman Yeilding, Philippe Szapary, et al.
BMC Dermatology|May 9, 2015
Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasisFernando Valenzuela, Kim A Papp, David Pariser, et al.
Pageof 22

Showing results (51-60 of 219) with videos related to

Sort By:
Pageof 22
Journal of the American Academy of Dermatology|November 27, 2002
A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisGerald G Krueger, Kim A Papp, Dow B Stough, et al.
Journal of Cutaneous Medicine and Surgery|April 25, 2006
Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approachesRichard G Langley, Vincent Ho, Charles Lynde, et al.
American Journal of Clinical Dermatology|November 13, 2018
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 StudiesApril W Armstrong, Kristian Reich, Peter Foley, et al.
American Journal of Clinical Dermatology|September 8, 2019
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II StudyMark G Lebwohl, Andrew Blauvelt, Alan Menter, et al.
Journal of Cutaneous Medicine and Surgery|February 23, 2018
OBSERVE-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United StatesKim A Papp, Marc Bourcier, Yves Poulin, et al.
Journal of the American Academy of Dermatology|September 21, 2010
Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult populationKim A Papp, Yves Poulin, Robert Bissonnette, et al.
The Journal of Dermatological Treatment|July 15, 2020
Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1Christopher E M Griffiths, Kim A Papp, Michael Song, et al.
Journal of the American Academy of Dermatology|July 21, 2015
Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasisAlan Menter, Diamant Thaçi, Kim A Papp, et al.
Journal of the American Academy of Dermatology|July 6, 2010
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendationsMark Lebwohl, Newman Yeilding, Philippe Szapary, et al.
BMC Dermatology|May 9, 2015
Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasisFernando Valenzuela, Kim A Papp, David Pariser, et al.
Pageof 22